WS MANAGEMENT LLLP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
WS MANAGEMENT LLLP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$856,782
-19.1%
18,8760.0%0.07%
-22.5%
Q2 2023$1,059,699
+24.1%
18,8760.0%0.09%
-1.1%
Q1 2023$853,761
+11.3%
18,8760.0%0.09%
+36.4%
Q4 2022$767,309
-37.8%
18,8760.0%0.07%
-41.1%
Q3 2022$1,234,000
+7.6%
18,8760.0%0.11%
+20.4%
Q2 2022$1,147,000
-3.2%
18,8760.0%0.09%
+60.3%
Q1 2022$1,185,000
-17.1%
18,8760.0%0.06%
-49.1%
Q4 2021$1,430,000
-32.3%
18,8760.0%0.11%
-49.1%
Q3 2021$2,113,000
-30.9%
18,8760.0%0.22%
-25.6%
Q2 2021$3,056,000
+32.9%
18,8760.0%0.30%
+26.5%
Q1 2021$2,300,000
-24.3%
18,876
-4.9%
0.24%
-24.4%
Q4 2020$3,038,000
+83.1%
19,8400.0%0.32%
+76.0%
Q3 2020$1,659,000
+13.8%
19,8400.0%0.18%0.0%
Q2 2020$1,458,000
+47.9%
19,840
-14.7%
0.18%
+65.7%
Q1 2020$986,000
-33.7%
23,252
-4.8%
0.11%
-15.0%
Q4 2019$1,487,000
+48.6%
24,4200.0%0.13%
+62.8%
Q3 2019$1,001,000
-21.6%
24,420
-9.9%
0.08%
-6.0%
Q2 2019$1,277,000
+17.9%
27,112
-10.6%
0.08%
+25.8%
Q1 2019$1,083,000
+10.2%
30,316
-11.9%
0.07%
+37.5%
Q4 2018$983,000
-61.1%
34,397
-39.7%
0.05%
-42.2%
Q3 2018$2,528,000
-24.5%
57,0000.0%0.08%
-11.7%
Q2 2018$3,349,00057,0000.09%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders